Online citations, reference lists, and bibliographies.
← Back to Search

Medical Imaging In Personalised Medicine: A White Paper Of The Research Committee Of The European Society Of Radiology (ESR)

European Society of Radiology
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
AbstractThe future of medicine lies in early diagnosis and individually tailored treatments, a concept that has been designated ‘personalised medicine’ (PM), which aims to deliver the right treatment to the right patient at the right time. Medical imaging has always been personalised and is fundamental to almost all aspects of PM. It is instrumental in solving clinical differential diagnoses. Imaging procedures are tailored to the clinical problem and patient characteristics. Screening for preclinical disease is done with imaging. Stratification based on imaging biomarkers can help identify individuals suited for preventive intervention. Treatment decisions are based on the in vivo visualisation of the location and extent of an abnormality, as well as the loco-regional physiological, biochemical and biological processes using structural and molecular imaging. Image-guided biopsy provides relevant tissue specimens for genetic/molecular characterisation. In addition, radiogenomics relate imaging biomarkers to these genetic and molecular features. Furthermore, imaging is essential to patient-tailored therapy planning, therapy monitoring and follow-up of disease, as well as targeting non-invasive or minimally invasive treatments, especially with the rise of theranostics. Radiologists need to be prepared for this new paradigm as it will mean changes in training, clinical practice and in research. Key Points • Medical imaging is a key component in personalised medicine • Personalised prevention will rely on image-based screening programmes • Anatomical, functional and molecular imaging biomarkers affect decisions on the type and intensity of treatment • Treatment response assessment with imaging will improve personalised treatment • Image-based invasive intervention integrates personalised diagnosis and personalised treatment
This paper references
10.1056/NEJMRA043186
Trastuzumab--mechanism of action and use in clinical practice.
C. Hudis (2007)
10.2214/AJR.13.11728
Indeterminate lung nodules in cancer patients: pretest probability of malignancy and the role of 18F-FDG PET/CT.
L. Evangelista (2014)
10.1016/S0140-6736(12)61611-0
The benefits and harms of breast cancer screening: an independent review
Independent UK Panel on Breast Cancer Screening (2012)
Metastatic ovarian and primary peritoneal cancer:assessing chemotherapy response with diffusion-weighted MR imaging—value of histogram analysis of apparent diffusion coefficients
E. Cancer (2011)
10.2214/AJR.11.6797
Molecular theranostics: a primer for the imaging professional.
D. Y. Lee (2011)
10.1215/S1522851705000529
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas.
G. Shah (2006)
NF - kappaB protein expression associates with ( 18 ) FFDG PET tumor uptake in non - small
VS Nair (2014)
Personalising health and care. https:// ec.europa.eu/research/participants/portal/desktop/en/opportunities/ h2020/topics
(2014)
10.1016/j.acra.2009.06.019
Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker.
A. Buckler (2010)
Real-time contrastenhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings
F Cornelis (2013)
Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study.
S. Esfahani (2013)
10.1056/NEJMc081780
Sorafenib in advanced hepatocellular carcinoma.
G. Spinzi (2008)
10.1378/chest.12-2355
Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
G. Silvestri (2013)
10.1148/radiol.13130663
Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.
C. Karlo (2014)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
10.1007/s12094-014-1204-8
Impact of initial FDG PET/CT in the management plan of patients with locally advanced head and neck cancer
F. Arias (2014)
10.1016/j.radonc.2011.07.029
Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
K. Hendrickson (2011)
10.1056/NEJMoa0906085
Management of lung nodules detected by volume CT scanning.
R. V. van Klaveren (2009)
10.3310/hta17200
The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
G. Mowatt (2013)
10.1016/j.ejvs.2010.09.011
Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery.
F. Moll (2011)
Personalising health and care
ESUR guidelines . http://www.esur.org/esur-guidelines
(2014)
10.1007/s13244-011-0125-0
Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR)
T. Beyer (2011)
10.1007/s00330-011-2300-6
Radiation dose considerations by intra-individual Monte Carlo simulations in dual source spiral coronary computed tomography angiography with electrocardiogram-triggered tube current modulation and adaptive pitch
M. May (2011)
National Institute of Health. National Human Genome Research Institute (2015) Talking Glossary of Genetic Terms
Wikipedia
10.1161/01.STR.0000054671.71777.C7
Reanalysis of the Final Results of the European Carotid Surgery Trial
P. Rothwell (2003)
10.1016/j.drudis.2008.05.009
Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine.
W. Eckelman (2008)
PET-directed, 3D Ultrasound-guided prostate biopsy.
B. Fei (2013)
Predicting response to Anti-TNF Agents for the treatment of crohn’s disease
CA Siegel (2009)
European Society for Medical Oncology ESMO Clinical Practice Guidelines. http://www.esmo.org/Guidelines
(2014)
10.1148/radiol.10091362
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
L. Fournier (2010)
10.1016/j.diii.2012.06.007
Ultrasound-guided lymph node sampling in the initial management of breast cancer.
C. Balu-Maestro (2013)
10.1136/bmj.d1951
Making the best use of clinical radiology
D. J. Remedios (2011)
10.1371/journal.pone.0025451
Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme
P. Zinn (2011)
10.1093/ejcts/ezu028
Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.
P. D. De Leyn (2014)
10.1148/radiol.14140531
History, evolution, and current status of radiologic imaging tests for colorectal cancer screening.
M. Levine (2014)
Science policy Briefing 28, Medical Imaging for Improved Patient Care
Usefulness of contrast enhanced ultrasound guidance in percutaneous biopsies of liver tumors.
Z. Sparchez (2011)
10.1097/MNM.0b013e32831af204
Impact of fluorodeoxyglucose PET on the management of esophageal cancer
Ali Salavati (2009)
10.1016/j.ejrad.2009.01.050
Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging.
Aaron M Rutman (2009)
10.7326/0003-4819-156-6-201203200-00006
Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification
M. Kavousi (2012)
10.1016/S0140-6736(02)08352-6
Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial
H. Tinteren (2002)
10.1038/nmat2766
Filled and glycosylated carbon nanotubes for in vivo radioemitter localization and imaging.
S. Y. Hong (2010)
10.1200/JCO.2003.01.144
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.
J. Erasmus (2003)
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18 Ffluoromisonidazole PET/CT study
F Hugonnet (2011)
10.1016/j.ijpharm.2011.02.010
'Personalised medicine' through 'personalised medicines': time to integrate advanced, non-invasive imaging approaches and smart drug delivery systems.
D. Crommelin (2011)
10.1038/ncomms5006
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
H. Aerts (2014)
Iodine - 131metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age
J deKraker (2008)
Insights Imaging
(2015)
10.1016/j.addr.2010.07.009
Nanoparticle-based theranostic agents.
J. Xie (2010)
10.4329/wjr.v3.i11.256
Current status of low dose multi-detector CT in the urinary tract.
Mi Kim Sung (2011)
10.2174/092986607780090874
Radiolabeled peptides and proteins in cancer therapy.
C. Wängler (2007)
Rad i o i od i n a t e d metaiodobenzylguanidine treatment of neuroendocrine tumors in adults
EJ Postema (2009)
10.1148/radiol.13132195
Behind the numbers: Decoding molecular phenotypes with radiogenomics--guiding principles and technical considerations.
M. Kuo (2014)
Response assessment in oncology: limitations of anatomic response criteria in the era of tailored treatments.
C. Carnaghi (2011)
10.2214/AJR.11.7163
Next generation radiologic-pathologic correlation in oncology: Rad-Path 2.0.
M. Kuo (2011)
10.1093/jnci/djq099
Overdiagnosis in cancer.
H. Welch (2010)
AEG-1 promotermediated imaging of prostate cancer
A Bhatnagar (2014)
of neuroendocrine tumors in adults
Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.
J. Czernin (2007)
10.1016/j.jacc.2013.06.015
Meta-analysis and systematic review of the predictive value of carotid plaque hemorrhage on cerebrovascular events by magnetic resonance imaging.
T. Saam (2013)
10.1007/s00259-013-2686-2
Current role of FDG PET/CT in lymphoma
L. Kostakoglu (2013)
10.1166/JNN.2011.3267
Preparation, characterization, cytotoxicity and drug release behavior of liposome-enveloped paclitaxel/Fe3O4 nanoparticles.
M. Kim (2011)
10.1073/pnas.0801279105
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules
M. Diehn (2008)
ACR Appropriateness Criteria http://www.acr.org/Quality-Safety/Appropriateness- Criteria
(2014)
10.1007/s11547-014-0401-4
Ct-guided bone biopsy in cancer patients with suspected bone metastases: retrospective review of 308 procedures
L. Monfardini (2014)
10.1158/1078-0432.CCR-07-0204
Spatio-Temporal Control of Gene Expression and Cancer Treatment Using Magnetic Resonance Imaging–Guided Focused Ultrasound
C. Moonen (2007)
10.1148/radiol.13120985
Breast intervention: how I do it.
M. Mahoney (2013)
10.1088/0952-4746/33/3/621
Paediatric x-ray radiation dose reduction and image quality analysis.
L. Martin (2013)
10.1148/radiol.11110252
Oncologic imaging: a guiding hand of personalized cancer care.
H. Hricak (2011)
10.1016/j.jacc.2013.09.063
Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects.
Y. Ben-Shlomo (2014)
10.1038/nbt1306
Decoding global gene expression programs in liver cancer by noninvasive imaging
E. Segal (2007)
10.1097/CCO.0b013e3283373d5c
‘Image and treat’: an individualized approach to urological tumors
K. Bouchelouche (2010)
10.1148/RADIOL.2252011604
CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
S. Prasad (2002)
List of cleared or approved companion diagnostic devices (In Vitro and Imaging Tools). http://www.fda.gov/MedicalDevices
U S Food (2014)
Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. http://dels.nas.edu/ Report/Toward-Precision-Medicine-Building-Knowledge/13284
(2011)
10.1148/radiol.09090369
Body size indexes for optimizing iodine dose for aortic and hepatic enhancement at multidetector CT: comparison of total body weight, lean body weight, and blood volume.
H. Kondo (2010)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
S. Eschmann (2005)
10.1089/CBR.2007.0417
Molecular imaging and personalized medicine: an uncertain future.
A. Nunn (2007)
10.1016/J.RADONC.2006.07.033
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients.
D. Thorwarth (2006)
Molecular imaging as a step towards personalized medicine
M Berger (2006)
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.2214/AJR.09.3437
Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer.
L. Mannelli (2010)
10.1148/radiol.11110577
Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients.
S. Kyriazi (2011)
10.2967/jnumed.107.045963
Tumor Receptor Imaging
D. Mankoff (2008)
10.3174/ajnr.A0538
Incorporating Functional MR Imaging into Diffusion Tensor Tractography in the Preoperative Assessment of the Corticospinal Tract in Patients with Brain Tumors
M. Smits (2007)
10.1038/nrendo.2009.105
Peptide-receptor radionuclide therapy for endocrine tumors
M. Essen (2009)
10.1200/JCO.2006.09.9515
Advances in image-guided radiation therapy.
L. Dawson (2007)
Next generation radiologicpathologic correlation in oncology : RadPath 2 . 0
A Salavati (2009)
Eurosafe Imaging, Together for patient safety
Esr Eurosafe Imaging
Personalised medicine for the European citizen -towards more precise medicine for the diagnosis, treatment and prevention of disease
10.1016/j.ejca.2008.10.031
Lessons learned from independent central review.
R. Ford (2009)
10.1016/j.biomaterials.2010.10.050
Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy.
K. Kono (2011)
10.1159/000068820
Combined Positron Emission Tomography and Magnetic Resonance Imaging for the Planning of Stereotactic Brain Biopsies in Children: Experience in 9 Cases
B. Pirotte (2003)
10.2214/AJR.11.7824
Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape.
S. Yamamoto (2012)
Tumormetabolism and blood flow changes by positron emission tomography : relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
JH Thrall (2009)
List of cleared or approved companion diagnostic devices
(2014)
10.1016/j.ijrobp.2013.08.001
Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
N. Nakajima (2013)
10.1007/s00330-014-3197-7
Topogram-based automated selection of the tube potential and current in thoraco-abdominal trauma CT – a comparison to fixed kV with mAs modulation alone
C. Frellesen (2014)
10.1148/radiol.10091760
Multiparametric imaging of tumor response to therapy.
A. Padhani (2010)
10.1200/JCO.2007.15.4385
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
L. K. Dunnwald (2008)
10.2967/jnumed.108.057307
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
R. Wahl (2009)
10.1159/000346087
European Stroke Organization Guidelines for the Management of Intracranial Aneurysms and Subarachnoid Haemorrhage
T. Steiner (2013)
10.1016/j.ejca.2008.01.010
Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
J. de Kraker (2008)
10.2967/jnumed.108.057224
Monitoring and Predicting Response to Therapy with 18F-FDG PET in Colorectal Cancer: A Systematic Review
L. de Geus-Oei (2009)
10.1102/1470-7330.2005.0028
What the clinician wants to know: surgical perspective and ultrasound for lymph node imaging of the neck
M. V. D. van den Brekel (2005)
10.1016/j.lungcan.2013.11.001
NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.
V. Nair (2014)
10.1148/radiol.13130078
Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation.
N. Jamshidi (2014)
10.1007/s10554-012-0170-x
Optimizing contrast medium injection protocol individually with body weight for high-pitch prospective ECG-triggering coronary CT angiography
J. Liu (2012)
10.1159/000347201
The Size of the Problem: Clinical Algorithms
A. Forner (2013)
10.1002/ijc.22134
Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON)
C. V. van Iersel (2007)
10.1002/0471224839.ch4
Personalized medicine.
Ginny Allain (2012)
Nuclear imaging in cancer theranostics.
S. Del Vecchio (2007)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar